Common gamma chain (γc) cytokines differentially potentiate TNFR family signaling in antigen-activated CD8+ T cells

Journal for ImmunoTherapy of Cancer

Volumn 2, Issue 1, 2014, Pages

  McNamara, Michael J ^a   Kasiewicz, Melissa J ^a   Linch, Stefanie N ^a   Dubay, Christopher ^a   Redmond, William L ^a  

^a EARLE A CHILES RESEARCH INSTITUTE   (United States)

Author keywords

CD8+ T cell; Common gamma chain cytokines; IL 2; Immunotherapy; OX40; TNFR

Indexed keywords

BIM PROTEIN; CD134 ANTIGEN; CD137 ANTIGEN; CD272 ANTIGEN; CD69 ANTIGEN; CD8 ANTIGEN; COMPLEMENTARY DNA; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FAS LIGAND; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; INDUCIBLE T CELL COSTIMULATOR; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR GAMMA; INTERLEUKIN 21; INTERLEUKIN 4; INTERLEUKIN 9 RECEPTOR; KI 67 ANTIGEN; MESSENGER RNA; NATURAL KILLER CELL LECTIN LIKE RECEPTOR; NATURAL KILLER CELL LECTIN LIKE RECEPTOR G1; PERFORIN; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN BCL 2; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL DIFFERENTIATION; CELL ISOLATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; GENETIC ANALYSIS; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA ISOLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

EID: 84977108838     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-014-0028-y     Document Type: Article

References (68)

1. Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol 2009, 9(7):480-490. 10.1038/nri2580, 19543225.
2. Liao W, Lin JX, Leonard WJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 2013, 38(1):13-25. 10.1016/j.immuni.2013.01.004, 23352221.
3. Liao W, Lin JX, Leonard WJ. IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr Opin Immunol 2011, 23(5):598-604. 10.1016/j.coi.2011.08.003, 21889323.
4. Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, Kammula US, Sherry RM, Royal RE, Steinberg SM, Rosenberg S. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 2008, 113(2):293-301. 10.1002/cncr.23552, 18457330.
5. Kim H, Kwon B, Sin JI. Combined stimulation of IL-2 and 4-1BB receptors augments the antitumor activity of E7 DNA vaccines by increasing Ag-specific CTL responses. PLoS One 2013, 8(12):e83765. 10.1371/journal.pone.0083765, 24391824.
6. Redmond WL, Triplett T, Floyd K, Weinberg AD. Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression. PLoS One 2012, 7(4):e34467. 10.1371/journal.pone.0034467, 22496812.
7. Kaech SM, Hemby S, Kersh E, Ahmed R. Molecular and functional profiling of memory CD8 T cell differentiation. Cell 2002, 111(6):837-851. 10.1016/S0092-8674(02)01139-X, 12526810.
8. Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2002, 2(4):251-262. 10.1038/nri778, 12001996.
9. Woodland DL, Dutton RW. Heterogeneity of CD4(+) and CD8(+) T cells. Curr Opin Immunol 2003, 15(3):336-342. 10.1016/S0952-7915(03)00037-2, 12787761.
10. Cox MA, Harrington LE, Zajac AJ. Cytokines and the inception of CD8 T cell responses. Trends Immunol 2011, 32(4):180-186. 10.1016/j.it.2011.01.004, 21371940.
11. Shuai K, Liu B. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 2003, 3(11):900-911. 10.1038/nri1226, 14668806.
12. Melero I, Hirschhorn-Cymerman D, Morales-Kastresana A, Sanmamed MF, Wolchok JD. Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin Cancer Res 2013, 19(5):1044-1053. 10.1158/1078-0432.CCR-12-2065, 23460535.
13. Chakir H, Wang H, Lefebvre DE, Webb J, Scott FW. T-bet/GATA-3 ratio as a measure of the Th1/Th2 cytokine profile in mixed cell populations: predominant role of GATA-3. J Immunol Methods 2003, 278(1-2):157-169. 10.1016/S0022-1759(03)00200-X, 12957404.
14. Sullivan BM, Juedes A, Szabo SJ, von Herrath M, Glimcher LH. Antigen-driven effector CD8 T cell function regulated by T-bet. Proc Natl Acad Sci U S A 2003, 100(26):15818-15823. 10.1073/pnas.2636938100, 14673093.
15. Correia MP, Costa AV, Uhrberg M, Cardoso EM, Arosa FA. IL-15 induces CD8+ T cells to acquire functional NK receptors capable of modulating cytotoxicity and cytokine secretion. Immunobiology 2010, 216(5):604-612. 10.1016/j.imbio.2010.09.012, 20956026.
16. Pulle G, Vidric M, Watts TH. IL-15-dependent induction of 4-1BB promotes antigen-independent CD8 memory T cell survival. J Immunol 2006, 176(5):2739-2748. 10.4049/jimmunol.176.5.2739, 16493029.
17. Snell LM, Lin GH, Watts TH. IL-15-dependent upregulation of GITR on CD8 memory phenotype T cells in the bone marrow relative to spleen and lymph node suggests the bone marrow as a site of superior bioavailability of IL-15. J Immunol 2012, 188(12):5915-5923. 10.4049/jimmunol.1103270, 22581858.
18. White L, Krishnan S, Strbo N, Liu H, Kolber MA, Lichtenheld MG, Pahwa RN, Pahwa S. Differential effects of IL-21 and IL-15 on perforin expression, lysosomal degranulation, and proliferation in CD8 T cells of patients with human immunodeficiency virus-1 (HIV). Blood 2007, 109(9):3873-3880. 10.1182/blood-2006-09-045278, 17192392.
19. Zeng R, Spolski R, Finkelstein SE, Oh S, Kovanen PE, Hinrichs CS, Pise-Masison CA, Radonovich MF, Brady JN, Restifo NP, Berzofsky JA, Leonard WJ. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med 2005, 201(1):139-148. 10.1084/jem.20041057, 15630141.
20. Lanier LL. Back to the future-defining NK cells and T cells. Eur J Immunol 2007, 37(6):1424-1426. 10.1002/eji.200737418, 17523211.
21. Macon WR, Williams ME, Greer JP, Hammer RD, Glick AD, Collins RD, Cousar JB. Natural killer-like T-cell lymphomas: aggressive lymphomas of T-large granular lymphocytes. Blood 1996, 87(4):1474-1483. 8608238.
22. Levy Y, Sereti I, Tambussi G, Routy JP, Lelievre JD, Delfraissy JF, Molina JM, Fischl M, Goujard C, Rodriguez B, Rouzioux C, Avettand-Fenoel V, Croughs T, Beq S, Morre M, Poulin JF, Sekaly RP, Thiebaut R, Lederman MM. Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study. Clin Infect Dis 2012, 55(2):291-300. 10.1093/cid/cis383, 22550117.
23. Meazza R, Azzarone B, Orengo AM, Ferrini S. Role of common-gamma chain cytokines in NK cell development and function: perspectives for immunotherapy. J Biomed Biotechnol 2011, 2011:861920. 10.1155/2011/861920, 21716670.
24. Rosenberg SA, Sportes C, Ahmadzadeh M, Fry TJ, Ngo LT, Schwarz SL, Stetler-Stevenson M, Morton KE, Mavroukakis SA, Morre M, Buffet R, Mackall CL, Gress RE. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother 2006, 29(3):313-319. 10.1097/01.cji.0000210386.55951.c2, 16699374.
25. Schluns KS, Kieper WC, Jameson SC, Lefrancois L. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat Immunol 2000, 1(5):426-432. 10.1038/80868, 11062503.
26. Waldmann TA, Lugli E, Roederer M, Perera LP, Smedley JV, Macallister RP, Goldman CK, Bryant BR, Decker JM, Fleisher TA, Lane HC, Sneller MC, Kurlander RJ, Kleiner DE, Pletcher JM, Figg WD, Yovandich JL, Creekmore SP. Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood 2011, 117(18):4787-4795. 10.1182/blood-2010-10-311456, 21385847.
27. Yu Y, Zitzner JR, Houlihan J, Herrera N, Xu L, Miller J, Mathew JM, Tambur AR, Luo X. Common gamma chain cytokines promote rapid in vitro expansion of allo-specific human CD8+ suppressor T cells. PLoS One 2011, 6(12):e28948. 10.1371/journal.pone.0028948, 22194954.
28. Frederiksen KS, Lundsgaard D, Freeman JA, Hughes SD, Holm TL, Skrumsager BK, Petri A, Hansen LT, McArthur GA, Davis ID, Skak K. IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol Immunother 2008, 57(10):1439-1449. 10.1007/s00262-008-0479-4, 18286285.
29. He H, Wisner P, Yang G, Hu HM, Haley D, Miller W, O'Hara A, Alvord WG, Clegg CH, Fox BA, Urba WJ, Walker EB. Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model. J Transl Med 2006, 4:24. 10.1186/1479-5876-4-24, 16772043.
30. Santegoets SJ, Turksma AW, Suhoski MM, Stam AG, Albelda SM, Hooijberg E, Scheper RJ, van den Eertwegh AJ, Gerritsen WR, Powell DJ, June CH, de Gruijl TD. IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells. J Transl Med 2013, 11:37. 10.1186/1479-5876-11-37, 23402380.
31. Sondergaard H, Frederiksen KS, Thygesen P, Galsgaard ED, Skak K, Kristjansen PE, Odum N, Kragh M. Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors. Cancer Immunol Immunother 2007, 56(9):1417-1428. 10.1007/s00262-007-0285-4, 17285290.
32. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004, 4(7):540-550. 10.1038/nrc1388, 15229479.
33. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006, 354(6):610-621. 10.1056/NEJMra052723, 16467548.
34. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007, 7(9):678-689. 10.1038/nri2156, 17717539.
35. Ingersoll MA, Platt AM, Potteaux S, Randolph GJ. Monocyte trafficking in acute and chronic inflammation. Trends Immunol 2011, 32(10):470-477. 10.1016/j.it.2011.05.001, 21664185.
36. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996, 383(6603):787-793. 10.1038/383787a0, 8893001.
37. Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol 2002, 2(12):933-944. 10.1038/nri954, 12461566.
38. Sad S, Marcotte R, Mosmann TR. Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines. Immunity 1995, 2(3):271-279. 10.1016/1074-7613(95)90051-9, 7697544.
39. Weninger W, Manjunath N, von Andrian UH. Migration and differentiation of CD8+ T cells. Immunol Rev 2002, 186:221-233. 10.1034/j.1600-065X.2002.18618.x, 12234374.
40. Dobrzanski MJ, Reome JB, Dutton RW. Therapeutic effects of tumor-reactive type 1 and type 2 CD8+ T cell subpopulations in established pulmonary metastases. J Immunol 1999, 162(11):6671-6680. 10352285.
41. Helmich BK, Dutton RW. The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: factors that determine the relative effectiveness and homing properties of Tc1 and Tc2 effectors. J Immunol 2001, 166(11):6500-6508. 10.4049/jimmunol.166.11.6500, 11359800.
42. Kemp RA, Ronchese F. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity. J Immunol 2001, 167(11):6497-6502. 10.4049/jimmunol.167.11.6497, 11714817.
43. Dobrzanski MJ, Reome JB, Hollenbaugh JA, Dutton RW. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses. J Immunol 2004, 172(3):1380-1390. 10.4049/jimmunol.172.3.1380, 14734713.
44. Kemp RA, Backstrom BT, Ronchese F. The phenotype of type 1 and type 2 CD8+ T cells activated in vitro is affected by culture conditions and correlates with effector activity. Immunology 2005, 115(3):315-324. 10.1111/j.1365-2567.2005.02168.x, 15946249.
45. Pai SY, Truitt ML, Ho IC. GATA-3 deficiency abrogates the development and maintenance of T helper type 2 cells. Proc Natl Acad Sci U S A 2004, 101(7):1993-1998. 10.1073/pnas.0308697100, 14769923.
46. Seki N, Miyazaki M, Suzuki W, Hayashi K, Arima K, Myburgh E, Izuhara K, Brombacher F, Kubo M. IL-4-induced GATA-3 expression is a time-restricted instruction switch for Th2 cell differentiation. J Immunol 2004, 172(10):6158-6166. 10.4049/jimmunol.172.10.6158, 15128803.
47. Tai TS, Pai SY, Ho IC. GATA-3 regulates the homeostasis and activation of CD8+ T cells. J Immunol 2012, 190(1):428-437. 10.4049/jimmunol.1201361, 23225883.
48. Zhu J, Yamane H, Cote-Sierra J, Guo L, Paul WE. GATA-3 promotes Th2 responses through three different mechanisms: induction of Th2 cytokine production, selective growth of Th2 cells and inhibition of Th1 cell-specific factors. Cell Res 2006, 16(1):3-10. 10.1038/sj.cr.7310002, 16467870.
49. Kallies A. Distinct regulation of effector and memory T-cell differentiation. Immunol Cell Biol 2008, 86(4):325-332. 10.1038/icb.2008.16, 18362944.
50. Mullen AC, High FA, Hutchins AS, Lee HW, Villarino AV, Livingston DM, Kung AL, Cereb N, Yao TP, Yang SY, Reiner SL. Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. Science 2001, 292(5523):1907-1910. 10.1126/science.1059835, 11397944.
51. Lighvani AA, Frucht DM, Jankovic D, Yamane H, Aliberti J, Hissong BD, Nguyen BV, Gadina M, Sher A, Paul WE, O'Shea JJ. T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells. Proc Natl Acad Sci U S A 2001, 98(26):15137-15142. 10.1073/pnas.261570598, 11752460.
52. Assarsson E, Kambayashi T, Sandberg JK, Hong S, Taniguchi M, Van Kaer L, Ljunggren HG, Chambers BJ. CD8+ T cells rapidly acquire NK1.1 and NK cell-associated molecules upon stimulation in vitro and in vivo. J Immunol 2000, 165(7):3673-3679. 10.4049/jimmunol.165.7.3673, 11034371.
53. Laouar A, Manocha M, Wan M, Yagita H, van Lier RA, Manjunath N. Cutting Edge: distinct NK receptor profiles are imprinted on CD8 T cells in the mucosa and periphery during the same antigen challenge: role of tissue-specific factors. J Immunol 2007, 178(2):652-656. 10.4049/jimmunol.178.2.652, 17202324.
54. Linn YC, Hui KM. Cytokine-induced NK-like T cells: from bench to bedside. J Biomed Biotechnol 2010, 2010:435745. 10.1155/2010/435745, 20368995.
55. McMahon CW, Raulet DH. Expression and function of NK cell receptors in CD8+ T cells. Curr Opin Immunol 2001, 13(4):465-470. 10.1016/S0952-7915(00)00242-9, 11498303.
56. Linn YC, Hui KM. Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia. Leuk Lymphoma 2003, 44(9):1457-1462. 10.1080/1042819031000083082, 14565644.
57. Toka FN, Kenney MA, Golde WT. Rapid and transient activation of gammadelta T cells to IFN-gamma production, NK cell-like killing, and antigen processing during acute virus infection. J Immunol 2011, 186(8):4853-4861. 10.4049/jimmunol.1003599, 21383249.
58. Zoll B, Lefterova P, Ebert O, Huhn D, Von Ruecker A, Schmidt-Wolf IG. Modulation of cell surface markers on NK-like T lymphocytes by using IL-2, IL-7 or IL-12 in vitro stimulation. Cytokine 2000, 12(9):1385-1390. 10.1006/cyto.2000.0733, 10975999.
59. Yosef N, Shalek AK, Gaublomme JT, Jin H, Lee Y, Awasthi A, Wu C, Karwacz K, Xiao S, Jorgolli M, Gennert D, Satija R, Shakya A, Lu DY, Trombetta JJ, Pillai MR, Ratcliffe PJ, Coleman ML, Bix M, Tantin D, Park H, Kuchroo VK, Regev A. Dynamic regulatory network controlling TH17 cell differentiation. Nature 2013, 496(7446):461-468. 10.1038/nature11981, 23467089.
60. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011, 480(7378):480-489. 10.1038/nature10673, 22193102.
61. Williams CA, Murray SE, Weinberg AD, Parker DC. OX40-mediated differentiation to effector function requires IL-2 receptor signaling but not CD28, CD40, IL-12Rbeta2, or T-bet. J Immunol 2007, 178(12):7694-7702. 10.4049/jimmunol.178.12.7694, 17548606.
62. Gong W, Xiao W, Qian L, Gong C, Hu M, Pan X, Ji M. Immobilized MHC class I chain-related protein A synergizes with IL-15 and soluble 4-1BB ligand to expand NK cells with high cytotoxicity ex vivo. Cell Mol Immunol 2010, 7(6):477-484. 10.1038/cmi.2010.41, 20871627.
63. Hinrichs CS, Spolski R, Paulos CM, Gattinoni L, Kerstann KW, Palmer DC, Klebanoff CA, Rosenberg SA, Leonard WJ, Restifo NP. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood 2008, 111(11):5326-5333. 10.1182/blood-2007-09-113050, 18276844.
64. Feau S, Arens R, Togher S, Schoenberger SP. Autocrine IL-2 is required for secondary population expansion of CD8(+) memory T cells. Nat Immunol 2011, 12(9):908-913. 10.1038/ni.2079, 21804558.
65. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003, 421(6925):852-856. 10.1038/nature01441, 12594515.
66. Williams MA, Tyznik AJ, Bevan MJ. Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature 2006, 441(7095):890-893. 10.1038/nature04790, 16778891.
67. Bousso P, Robey E. Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes. Nat Immunol 2003, 4(6):579-585. 10.1038/ni928, 12730692.
68. Grossman WJ, Verbsky JW, Tollefsen BL, Kemper C, Atkinson JP, Ley TJ. Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood 2004, 104(9):2840-2848. 10.1182/blood-2004-03-0859, 15238416.